COVID-19 disease. COVID-19, virus not identified
Conditions
Interventions
Intervention 1: Intervention group: will be mild patients receiving hydroxychloroquine sulfate (Amin Pharmaceutical company, Iran) at a dose of 400 mg twice a day for the first day and 200 mg twice a
Sponsors
Bandare-abbas University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: Age =20 years old Weight =35 kg Positive polymerase chain reaction (PCR) test for COVID-19 Non-hospitalized mild as well as hospitalized moderate patients Signed informed consent voluntarily and knowingly
Exclusion criteria
Exclusion criteria: Underlying diseases (AIDS, asthma, severe liver and kidney disease) History of Loiasis History of drug allergy to Ivermectin Use of anticoagulants (e.g. warfarin) and ACE inhibitors (e.g. captopril) Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Length of hospital stay. Timepoint: Until discharge date. Method of measurement: Questionnaire.;Need for ICU. Timepoint: Until discharge date. Method of measurement: Questionnaire.;Need for mechanical ventilation. Timepoint: Until discharge date. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of serious adverse reactions. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Fathalipour
Bandare-abbas University of Medical Sciences
Outcome results
None listed